がん治療関連心機能障害(CTRCD)
Saved in:
| Published in | Shinzo Vol. 52; no. 12; pp. 1324 - 1331 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | Japanese |
| Published |
公益財団法人 日本心臓財団
25.12.2020
Japan Heart Foundation |
| Online Access | Get full text |
| ISSN | 0586-4488 2186-3016 |
| DOI | 10.11281/shinzo.52.1324 |
Cover
| Author | 前嶋, 康浩 |
|---|---|
| Author_xml | – sequence: 1 fullname: 前嶋, 康浩 organization: 東京医科歯科大学大学院医歯学総合研究科 循環制御内科学 |
| BackLink | https://cir.nii.ac.jp/crid/1390572045479382528$$DView record in CiNii |
| BookMark | eNo9kL9KA0EYxBeJYIypfQGLWFzc_Xa_u91Sz78QECTWy96yZzbEi9yl0UqT1k4QFEHQysZCSxEfJiSatzAasZkZmOFXzCIpZd3MEbLMaJ0xkGytaPnsrFtHqDMOYo6Ugckw4JSFJVKmOM1CSLlAqkXhE0qpjJhSvExqw4vLYf9q_PL2edOfXD9Mzh9HH4Px0_3X4H1yezd6fq3FzYN4c3WJzKemU7jqn1fI4fZWM94NGvs7e_F6I2gDRxlwxwBEiCG3LkIuqaJCJSgdCqDW8lQyCZKjU6kzQprEIIKwCKlKTCiAV8jKjJt5r63_UcYVxQioQBEpLgGngArZmM3aRc8cOX2S-2OTn2qT97ztOD37QyNoBr86feW_tC2T67bh34-sZNg |
| ContentType | Journal Article |
| Copyright | 2020 公益財団法人 日本心臓財団 |
| Copyright_xml | – notice: 2020 公益財団法人 日本心臓財団 |
| DBID | RYH |
| DOI | 10.11281/shinzo.52.1324 |
| DatabaseName | CiNii Complete |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2186-3016 |
| EndPage | 1331 |
| ExternalDocumentID | 130008138253 article_shinzo_52_12_52_1324_article_char_ja |
| GroupedDBID | ALMA_UNASSIGNED_HOLDINGS JSF KQ8 MOJWN RJT RYH |
| ID | FETCH-LOGICAL-j2358-3e12246563ce753809049b58e5420cc3f8182835e9fea48aba5524c52f9ba6423 |
| ISSN | 0586-4488 |
| IngestDate | Fri Jun 27 01:00:03 EDT 2025 Wed Sep 03 06:31:02 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 12 |
| Language | Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j2358-3e12246563ce753809049b58e5420cc3f8182835e9fea48aba5524c52f9ba6423 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/shinzo/52/12/52_1324/_article/-char/ja |
| PageCount | 8 |
| ParticipantIDs | nii_cinii_1390572045479382528 jstage_primary_article_shinzo_52_12_52_1324_article_char_ja |
| PublicationCentury | 2000 |
| PublicationDate | 2020-12-25 |
| PublicationDateYYYYMMDD | 2020-12-25 |
| PublicationDate_xml | – month: 12 year: 2020 text: 2020-12-25 day: 25 |
| PublicationDecade | 2020 |
| PublicationTitle | Shinzo |
| PublicationTitleAlternate | 心臓 |
| PublicationTitle_FL | 心臓 Shinzo |
| PublicationYear | 2020 |
| Publisher | 公益財団法人 日本心臓財団 Japan Heart Foundation |
| Publisher_xml | – name: 公益財団法人 日本心臓財団 – name: Japan Heart Foundation |
| References | 28) Nishimura H, Okazaki T, Tanaka Y, et al：Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001；291：319-322 18) Losordo DW, Vale PR, Symes JF, et al：Gene therapy for myocardial angiogenesis：Initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998；98：2800-2804 13) Patnaik JL, Byers T, DiGuiseppi C, et al：Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer：A retrospective cohort study. Breast Cancer Res 2011；13：R64 19) Li W, Croce K, Steensma DP, et al：Vascular and metabolic implications of novel targeted cancer therapies：Focus on kinase inhibitors. J Am Coll Cardiol 2015；66：1160-1178 11) Woyach JA, Ruppert AS, Heerema NA, et al：Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated cll. N Engl J Med 2018；379：2517-2528 12) Caldeira D, Alves D, Costa J, et al：Ibrutinib increases the risk of hypertension and atrial fibrillation：Systematic review and meta-analysis. PLoS One 2019；14：e0211228 15) Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, et al：Genetic variants associated with cancer therapy-induced cardiomyopathy. Circulation 2019；140：31-41 3) van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG：Drug-drug interactions with tyrosine-kinase inhibitors：A clinical perspective. Lancet Oncol 2014；15：e315-326 14) Bowles EJ, Wellman R, Feigelson HS, et al：Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment：A retrospective cohort study. J Natl Cancer Inst 2012；104：1293-1305 25) Yasuda S, Kaikita K, Akao M, et al：Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med 2019；381：1103-1113 23) Young AM, Marshall A, Thirlwall J, et al：Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism：Results of a randomized trial(SELECT-D). J Clin Oncol 2018；36：2017-2023 29) Johnson DB, Balko JM, Compton ML, et al：Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016；375：1749-1755 7) Brixey AG, Light RW：Pleural effusions due to dasatinib. Curr Opin Pulm Med 2010；16：351-356 10) Anand K, Ensor J, Trachtenberg B, Bernicker E：Osimertinib-induced cardiotoxicity：A retrospective review of the fda adverse events reporting system(faers). J Am Coll Cardiol CardioOnc 2019；1：172-178 24) Agnelli G, Becattini C, Meyer G, et al：Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020；382：1599-1607 2) Khorana AA：Venous thromboembolism and prognosis in cancer. Thromb Res 2010；125：490-493 21) Farmakis D, Parissis J, Filippatos G：Insights into onco-cardiology：Atrial fibrillation in cancer. J Am Coll Cardiol 2014；63：945-953 31) Zhou YW, Zhu YJ, Wang MN, et al：Immune checkpoint inhibitor-associated cardiotoxicity：Current understanding on its mechanism, diagnosis and management. Front Pharmacol 2019；10：1350 20) Hall PS, Harshman LC, Srinivas S, Witteles RM：The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Heart Fail 2013；1：72-78 22) Raskob GE, van Es N, Verhamme P, et al：Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018；378：615-624 26) Curran CS, Sommers CL, Young HA, et al：Report on the 2018 cancer, autoimmunity, and immunology conference. J Immunol 2019；202：2823-2828 9) Zaborowska-Szmit M, Krzakowski M, Kowalski DM, Szmit S：Cardiovascular complications of systemic therapy in non-small-cell lung cancer. J Clin Med 2020；9：1268 5) Kerkelä R, Grazette L, Yacobi R, et al：Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006；12：908-916 6) Lekes D, Szadvari I, Krizanova O, et al：Nilotinib induces er stress and cell death in h9c2 cells. Physiol Res 2016；65：S505-S514 8) Casavecchia G, Galderisi M, Novo G, et al：Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib. Heart Fail Rev 2020；25：447-456 4) Okada K, Minamino T, Tsukamoto Y, et al：Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction：Possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis. Circulation 2004；110：705-712 16) Aminkeng F, Bhavsar AP, Visscher H, et al：A coding variant in rarg confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nat Genet 2015；47：1079-1084 17) Isner JM, Pieczek A, Schainfeld R, et al：Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996；348：370-374 27) Topalian SL, Hodi FS, Brahmer JR, et al：Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012；366：2443-2454 30) Awadalla M, Mahmood SS, Groarke JD, et al：Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis. J Am Coll Cardiol 2020；75：467-478 1) Ewer MS, Ewer SM：Cardiotoxicity of anticancer treatments. Nat Rev Cardiol 2015；12：547-558 |
| References_xml | – reference: 28) Nishimura H, Okazaki T, Tanaka Y, et al：Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001；291：319-322 – reference: 29) Johnson DB, Balko JM, Compton ML, et al：Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016；375：1749-1755 – reference: 27) Topalian SL, Hodi FS, Brahmer JR, et al：Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012；366：2443-2454 – reference: 10) Anand K, Ensor J, Trachtenberg B, Bernicker E：Osimertinib-induced cardiotoxicity：A retrospective review of the fda adverse events reporting system(faers). J Am Coll Cardiol CardioOnc 2019；1：172-178 – reference: 5) Kerkelä R, Grazette L, Yacobi R, et al：Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006；12：908-916 – reference: 19) Li W, Croce K, Steensma DP, et al：Vascular and metabolic implications of novel targeted cancer therapies：Focus on kinase inhibitors. J Am Coll Cardiol 2015；66：1160-1178 – reference: 20) Hall PS, Harshman LC, Srinivas S, Witteles RM：The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Heart Fail 2013；1：72-78 – reference: 4) Okada K, Minamino T, Tsukamoto Y, et al：Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction：Possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis. Circulation 2004；110：705-712 – reference: 6) Lekes D, Szadvari I, Krizanova O, et al：Nilotinib induces er stress and cell death in h9c2 cells. Physiol Res 2016；65：S505-S514 – reference: 24) Agnelli G, Becattini C, Meyer G, et al：Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020；382：1599-1607 – reference: 31) Zhou YW, Zhu YJ, Wang MN, et al：Immune checkpoint inhibitor-associated cardiotoxicity：Current understanding on its mechanism, diagnosis and management. Front Pharmacol 2019；10：1350 – reference: 3) van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG：Drug-drug interactions with tyrosine-kinase inhibitors：A clinical perspective. Lancet Oncol 2014；15：e315-326 – reference: 2) Khorana AA：Venous thromboembolism and prognosis in cancer. Thromb Res 2010；125：490-493 – reference: 9) Zaborowska-Szmit M, Krzakowski M, Kowalski DM, Szmit S：Cardiovascular complications of systemic therapy in non-small-cell lung cancer. J Clin Med 2020；9：1268 – reference: 12) Caldeira D, Alves D, Costa J, et al：Ibrutinib increases the risk of hypertension and atrial fibrillation：Systematic review and meta-analysis. PLoS One 2019；14：e0211228 – reference: 30) Awadalla M, Mahmood SS, Groarke JD, et al：Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis. J Am Coll Cardiol 2020；75：467-478 – reference: 11) Woyach JA, Ruppert AS, Heerema NA, et al：Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated cll. N Engl J Med 2018；379：2517-2528 – reference: 23) Young AM, Marshall A, Thirlwall J, et al：Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism：Results of a randomized trial(SELECT-D). J Clin Oncol 2018；36：2017-2023 – reference: 13) Patnaik JL, Byers T, DiGuiseppi C, et al：Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer：A retrospective cohort study. Breast Cancer Res 2011；13：R64 – reference: 26) Curran CS, Sommers CL, Young HA, et al：Report on the 2018 cancer, autoimmunity, and immunology conference. J Immunol 2019；202：2823-2828 – reference: 14) Bowles EJ, Wellman R, Feigelson HS, et al：Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment：A retrospective cohort study. J Natl Cancer Inst 2012；104：1293-1305 – reference: 17) Isner JM, Pieczek A, Schainfeld R, et al：Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996；348：370-374 – reference: 1) Ewer MS, Ewer SM：Cardiotoxicity of anticancer treatments. Nat Rev Cardiol 2015；12：547-558 – reference: 8) Casavecchia G, Galderisi M, Novo G, et al：Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib. Heart Fail Rev 2020；25：447-456 – reference: 22) Raskob GE, van Es N, Verhamme P, et al：Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018；378：615-624 – reference: 7) Brixey AG, Light RW：Pleural effusions due to dasatinib. Curr Opin Pulm Med 2010；16：351-356 – reference: 21) Farmakis D, Parissis J, Filippatos G：Insights into onco-cardiology：Atrial fibrillation in cancer. J Am Coll Cardiol 2014；63：945-953 – reference: 15) Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, et al：Genetic variants associated with cancer therapy-induced cardiomyopathy. Circulation 2019；140：31-41 – reference: 25) Yasuda S, Kaikita K, Akao M, et al：Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med 2019；381：1103-1113 – reference: 16) Aminkeng F, Bhavsar AP, Visscher H, et al：A coding variant in rarg confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nat Genet 2015；47：1079-1084 – reference: 18) Losordo DW, Vale PR, Symes JF, et al：Gene therapy for myocardial angiogenesis：Initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998；98：2800-2804 |
| SSID | ssib000871993 ssib005879815 ssib058494393 ssj0000605722 ssib002822027 |
| Score | 2.2499237 |
| SourceID | nii jstage |
| SourceType | Publisher |
| StartPage | 1324 |
| Title | がん治療関連心機能障害(CTRCD) |
| URI | https://www.jstage.jst.go.jp/article/shinzo/52/12/52_1324/_article/-char/ja https://cir.nii.ac.jp/crid/1390572045479382528 |
| Volume | 52 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | 心臓, 2020/12/25, Vol.52(12), pp.1324-1331 |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Colorado Digital library customDbUrl: eissn: 2186-3016 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000605722 issn: 0586-4488 databaseCode: KQ8 dateStart: 19690101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR09b9Qw1DrKwoKKAFGgqAOWilCOnB0ntpicXE4VCCTQVeoWJa4j3Q1XhK5Lp9KubEhIICQkmFgYYESIf8JStXD_gvec3F1KGSgslmO_PH885304fs-E3LQdf7MsAusxZo0XGFV4eWGlZ0A08LxQJu-gN_KDh-HaenBvQ2y0Wt8bp5a2x0Xb7PzRr-RfqAplQFf0kj0FZWdIoQDyQF9IgcKQ_hWNacpBE6QycRlGFadpSGNG45imEVUKC1NFVUi1y0ifaoARNO5R6YA11PZoKvEx7jpgTVWCMDqlMcefvP3HSXe6YzCctjzDAa9CUzP2gTUSWuo6kJDKGKnoHjSNI9dBwK2a2w3MHd2oXJPdAnFIACpxw4ip1NgODEx3sApKdDVUTpWgaeBw69tYpCKqhcsk7v3f-3kSUYMXChl6YElWrNq6MrxNywP-FDaZuWDNRcsarBnM7qAh5ju1p9hJEcIkyhDcANzZagvWnr94LC53TfWsAswEyzrMpQCeTSvRdS4bgv5-loHUwatF7j9qqr8Rnp9smr-4FzXnjzJSjVg6oCsq0B_5bA_RB1u0jvU5nZ86ehUO4s7xIYCKNQSDAyNJnBkNBg0tqr9Iztfmz4quOn6BtIb5RbJ68Oz5wd6Lo09ffrzam7x8N9l9f_ht_-jD25_7Xyev3xx-_Lzq1uCtS2S9l_aTNa--wcMbogu2xy3-uAWTgRsLdrH0FRikhZBWBMw3hpegLmLAP6tKmwcyL3IhWGAEK1WRg2XML5OF0dbIXiErlvslYyYqeGGDIMzzyJahypUNzCbgtUvkbjW87EkVpiU7DYGWyDLMSWYGmIJRhPOKwSlBekkmmLz6X9ivkXPzT-k6WRg_3bbLoMuOixtuQfwCrGN9mQ |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E3%81%8C%E3%82%93%E6%B2%BB%E7%99%82%E9%96%A2%E9%80%A3%E5%BF%83%E6%A9%9F%E8%83%BD%E9%9A%9C%E5%AE%B3%28CTRCD%29&rft.jtitle=%E5%BF%83%E8%87%93&rft.au=%E5%89%8D%E5%B6%8B%2C+%E5%BA%B7%E6%B5%A9&rft.date=2020-12-25&rft.pub=%E5%85%AC%E7%9B%8A%E8%B2%A1%E5%9B%A3%E6%B3%95%E4%BA%BA+%E6%97%A5%E6%9C%AC%E5%BF%83%E8%87%93%E8%B2%A1%E5%9B%A3&rft.issn=0586-4488&rft.eissn=2186-3016&rft.volume=52&rft.issue=12&rft.spage=1324&rft.epage=1331&rft_id=info:doi/10.11281%2Fshinzo.52.1324&rft.externalDocID=article_shinzo_52_12_52_1324_article_char_ja |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0586-4488&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0586-4488&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0586-4488&client=summon |